Skip to main content
An official website of the United States government

Genetic Mosaicism Study

Genetic mosaicism describes the presence of DNA alterations in only some of the body's cells; a person with mosaicism, therefore, has a mixture of normal and mosaic DNA in the same cell types. While mosaicism is not always harmful, it has been clinically recognized for decades and is associated with a number of adverse health outcomes, including cancer. Relatively little is known about the mechanisms that initiate and select for mosaic alterations. Mosaicism may serve as an informative genetic intermediate between normal and disease states.

DCEG researchers and their collaborators have found that both inherited germline variation (e.g., at TCL1A) and environmental exposures (e.g., smoking) may predispose to mosaicism in circulating leukocytes. Acquired mosaic alterations have abundant potential to inform cancer etiology and drive oncogenic change. The researchers have found evidence suggesting mosaicism increases risk for hematologic malignancies and select solid tumor subtypes, and can also impact telomere length and blood cell counts.

Studies have also examined sex chromosomes (XX in females and XY in males). In particular, mosaic Y loss has been found to be the most common large-scale detectable event in males. Ongoing genome-wide association studies of mosaic loss of chromosome Y and chromosome X seek to understand better genetic susceptibility to genetic mosaicism.

For more information, contact Mitchell Machiela.

Integrative Tumor Epidemiology Branch - Research Areas

Selected Publications

News Summaries of Research Findings

 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Genetic Mosaicism Study was originally published by the National Cancer Institute.”

Email